Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alba A Brandes

Showing results (121-130 of 178) with videos related to

Pageof 18
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 20, 2007
Prognostic value of health-related quality-of-life data in predicting survival in patients with anaplastic oligodendrogliomas, from a phase III EORTC brain cancer group studyMurielle E L Mauer, Martin J B Taphoorn, Andrew Bottomley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 18, 2010
IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor GroupMartin J van den Bent, Hendrikus J Dubbink, Yannick Marie, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 20, 2007
Health-related quality of life in patients treated for anaplastic oligodendroglioma with adjuvant chemotherapy: results of a European Organisation for Research and Treatment of Cancer randomized clinical trialMartin J B Taphoorn, Martin J van den Bent, Murielle E L Mauer, et al.
Future Oncology (London, England)|February 17, 2016
Patient outcomes following second surgery for recurrent glioblastomaAlba A Brandes, Marco Bartolotti, Alicia Tosoni, et al.
Diagnostics (Basel, Switzerland)|May 28, 2022
Molecular Characterization of Pancreatic Ductal Adenocarcinoma Using a Next-Generation Sequencing Custom-Designed Multigene PanelDeborah Malvi, Francesco Vasuri, Thais Maloberti, et al.
Neuro-Oncology Advances|November 12, 2021
Impact of lymphopenia on survival for elderly patients with glioblastoma: A secondary analysis of the CCTG CE.6 (EORTC 26062-22061, TROG03.01) randomized clinical trialAndrew J Song, Keyue Ding, Iyad Alnahhas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 26, 2023
Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 TrialTobias Kessler, Daniel Schrimpf, Laura Doerner, et al.
Neuro-Oncology Advances|January 31, 2022
Corrigendum to: Impact of lymphopenia on survival for elderly patients with glioblastoma: A secondary analysis of the CCTG CE.6 (EORTC 26062-22061, TROG 08.02) randomized clinical trialAndrew J Song, Keyue Ding, Iyad Alnahhas, et al.
JAMA Oncology|May 22, 2020
Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical TrialDavid A Reardon, Alba A Brandes, Antonio Omuro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 11, 2009
MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951Martin J van den Bent, Hendrikus J Dubbink, Marc Sanson, et al.
Pageof 18

Showing results (121-130 of 178) with videos related to

Sort By:
Pageof 18
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 20, 2007
Prognostic value of health-related quality-of-life data in predicting survival in patients with anaplastic oligodendrogliomas, from a phase III EORTC brain cancer group studyMurielle E L Mauer, Martin J B Taphoorn, Andrew Bottomley, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 18, 2010
IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor GroupMartin J van den Bent, Hendrikus J Dubbink, Yannick Marie, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 20, 2007
Health-related quality of life in patients treated for anaplastic oligodendroglioma with adjuvant chemotherapy: results of a European Organisation for Research and Treatment of Cancer randomized clinical trialMartin J B Taphoorn, Martin J van den Bent, Murielle E L Mauer, et al.
Future Oncology (London, England)|February 17, 2016
Patient outcomes following second surgery for recurrent glioblastomaAlba A Brandes, Marco Bartolotti, Alicia Tosoni, et al.
Diagnostics (Basel, Switzerland)|May 28, 2022
Molecular Characterization of Pancreatic Ductal Adenocarcinoma Using a Next-Generation Sequencing Custom-Designed Multigene PanelDeborah Malvi, Francesco Vasuri, Thais Maloberti, et al.
Neuro-Oncology Advances|November 12, 2021
Impact of lymphopenia on survival for elderly patients with glioblastoma: A secondary analysis of the CCTG CE.6 (EORTC 26062-22061, TROG03.01) randomized clinical trialAndrew J Song, Keyue Ding, Iyad Alnahhas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 26, 2023
Prognostic Markers of DNA Methylation and Next-Generation Sequencing in Progressive Glioblastoma from the EORTC-26101 TrialTobias Kessler, Daniel Schrimpf, Laura Doerner, et al.
Neuro-Oncology Advances|January 31, 2022
Corrigendum to: Impact of lymphopenia on survival for elderly patients with glioblastoma: A secondary analysis of the CCTG CE.6 (EORTC 26062-22061, TROG 08.02) randomized clinical trialAndrew J Song, Keyue Ding, Iyad Alnahhas, et al.
JAMA Oncology|May 22, 2020
Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical TrialDavid A Reardon, Alba A Brandes, Antonio Omuro, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 11, 2009
MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951Martin J van den Bent, Hendrikus J Dubbink, Marc Sanson, et al.
Pageof 18